Suspended
The Effect of Dosage of Caffeine on Intraocular Pressure in Healthy Subjects
What is being tested
decaffeinated coffee
+ regular dose coffee
+ high dose coffee
Other
Who is being recruted
From 20 to 35 Years
+6 Eligibility Criteria
How is the trial designed
Diagnostic Study
Placebo-Controlled
Interventional
Study Start: February 2013
Summary
Principal SponsorChiang Mai University
Study ContactDamrong Wiwatwongwana, M.D.More contacts
Last updated: February 15, 2013Sourced from a government-validated database.Claim as a partner
Study start date: February 1, 2013
Actual date on which the first participant was enrolled.decaffeinated coffee contains 0.5-2 mg of caffeine regular dose coffee contains 91.8 mg of caffeine high dose coffee contains 144 mg of caffeine all three groups' intraocular pressure will be measured with the Goldmann applanation tonometer at 4 timepoints: 0 minutes (baseline) 30 minutes after intake 60 minutes after intake 90 minutes after intake
Principal SponsorChiang Mai University
Study ContactDamrong Wiwatwongwana, M.D.More contacts
Last updated: February 15, 2013Sourced from a government-validated database.Claim as a partner
Protocol
This section provides details of the study plan, including how the study is designed and what the study is measuring.Design Details
60 patients to be enrolled
Total number of participants that the clinical trial aims to recruit.Diagnostic Study
Diagnostic studies focus on improving how we detect or confirm a disease. They test new tools or techniques that could provide faster or more accurate diagnoses.
Eligibility
Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.Criteria
Any sex
Biological sex of participants that are eligible to enroll.From 20 to 35 Years
Range of ages for which participants are eligible to join.Healthy volunteers allowed
If individuals who are healthy and do not have the condition being studied can participate.Criteria
3 inclusion criteria required to participate
healthy subjects
normal baseline intraocular pressure
normal central corneal thickness
3 exclusion criteria prevent from participating
any ocular disease
baseline intraocular pressure over 21 mmHg
central corneal thickness less than 520 microns or more than 540 microns
Study Plan
Find out more about all the medication administered in this study, their detailed description and what they involve.Treatment Groups
Study Objectives
3 intervention groups are designated in this study
33.333% chance of being blinded to the placebo group
Treatment Groups
Group I
Shamcontains 0.5-2 mg of caffeine
Group II
Active Comparatorcontains 91.8 mg of caffeine
Group III
Active Comparatorcontains 144 mg of caffeine
Study Objectives
Primary Objectives
Study Centers
These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.This study has 1 location
Recruiting
SuspendedOne Study Center